Medicenna Therapeutics Q3 2026 Earnings Report

Medicenna Therapeutics EPS Results

• Actual EPS: -$0.05
• Consensus EPS: -$0.04
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Medicenna Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Medicenna Therapeutics Announcement Details

• Quarter: Q3 2026
• Date: 2/12/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Medicenna Therapeutics (OTCMKTS:MDNAF) is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile. The company also advances additional discovery- and preclinical-stage programs that leverage its cytokine-engineering platform to address unmet needs in oncology and neuro-oncology.

Medicenna conducts clinical development programs and collaborates with academic and industry partners to advance its candidates through clinical trials. Headquartered in Canada, the company operates in the clinical research environment with study activity in North America and internationally. Its strategy emphasizes targeted delivery and molecular redesign of cytokines to improve efficacy and tolerability for patients with difficult-to-treat cancers and central nervous system malignancies.